Cargando…

Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial

COVID-19 is characterized by vascular inflammation and thrombosis, including elevations in P-selectin, a mediator of inflammation released by endothelial cells. We tested the effect of P-selectin inhibition on biomarkers of thrombosis and inflammation in patients with COVID-19. Hospitalized patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leucker, Thorsten M., Osburn, William O., Reventun, Paula, Smith, Kimberley, Claggett, Brian, Kirwan, Bridget-Anne, de Brouwer, Sophie, Williams, Marlene S., Gerstenblith, Gary, Hager, David N., Streiff, Michael B., Solomon, Scott D., Lowenstein, Charles J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653991/ https://www.ncbi.nlm.nih.gov/pubmed/34904132 http://dx.doi.org/10.1016/j.jacbts.2021.09.013

Ejemplares similares

P-Selectin Blockade in the Treatment of Painful Vaso-Occlusive Crises in Sickle Cell Disease: A Spotlight on Crizanlizumab
por: Karki, Nabin Raj, et al.
Publicado: (2021)

The transcriptional landscape of human liver endothelial cells
por: Toledano-Sanz, Pablo, et al.
Publicado: (2023)

Crizanlizumab: A CRITICAL Drug During a CRITICAL Time?
por: Gue, Ying X., et al.
Publicado: (2021)

Markers of endothelial cell activation are associated with the severity of pulmonary disease in COVID-19
por: Osburn, William O., et al.
Publicado: (2022)

High risk oral contraceptive hormones do not directly enhance endothelial cell procoagulant activity in vitro
por: Bouck, Emma G., et al.
Publicado: (2023)

Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease
por: Kanter, Julie, et al.
Publicado: (2022)

Successful Treatment of SCD-Related Priapism With Crizanlizumab: A Case Series
por: Idowu, Modupe, et al.
Publicado: (2023)

Impact of Crizanlizumab on Acute Medical Care Utilization in the Height of the COVID-19 Pandemic
por: Rao, Shivani, et al.
Publicado: (2021)

UK media reporting of NICE recommendation of crizanlizumab for patients with sickle cell disease
por: Buka, Richard J, et al.
Publicado: (2022)

Evolocumab, a PCSK9‐Monoclonal Antibody, Rapidly Reverses Coronary Artery Endothelial Dysfunction in People Living With HIV and People With Dyslipidemia
por: Leucker, Thorsten M., et al.
Publicado: (2020)

Real-World Data of Crizanlizumab in Sickle Cell Disease: A Single-Center Analysis
por: Cheplowitz, Halle, et al.
Publicado: (2023)

Effect of Sex on Coronary Endothelial Dysfunction in People Living With HIV
por: Minhas, Anum S., et al.
Publicado: (2022)

Profile of crizanlizumab and its potential in the prevention of pain crises in sickle cell disease: evidence to date
por: Riley, Tanya R, et al.
Publicado: (2019)

Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis
por: Thom, Howard, et al.
Publicado: (2020)

Recent Advances in Sickle-Cell Disease Therapies: A Review of Voxelotor, Crizanlizumab, and L-glutamine
por: Migotsky, Michael, et al.
Publicado: (2022)

5610357 REDUCTION IN BLOOD TRANSFUSION BURDEN FOLLOWING INITIATION OF VOXELOTOR OR CRIZANLIZUMAB: A CASE SERIES
por: Baruwa Etti, A., et al.
Publicado: (2023)

Lipoprotein(a) concentrations in acute myocardial infarction patients are not indicative of levels at six month follow-up
por: Ziogos, Efthymios, et al.
Publicado: (2023)

5613436 EXPERT CONSENSUS ON THE MANAGEMENT OF INFUSION-RELATED REACTIONS (IRRS) PRESENTING WITH PAIN IN PATIENTS RECEIVING CRIZANLIZUMAB
por: Kanter, J., et al.
Publicado: (2023)

PB2512: SAFETY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE: INTEGRATED POST-MARKETING SURVEILLANCE ANALYSIS
por: Abboud, Miguel, et al.
Publicado: (2023)

The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease
por: Delgado, Julio, et al.
Publicado: (2021)

Coronary Endothelial Dysfunction Is Associated With Elevated Serum PCSK9 Levels in People With HIV Independent of Low‐Density Lipoprotein Cholesterol
por: Leucker, Thorsten M., et al.
Publicado: (2018)

Systematic Review and Meta-Analysis of the Effect of Statins on Circulating E-Selectin, L-Selectin, and P-Selectin
por: Zinellu, Angelo, et al.
Publicado: (2021)

Restoring the biological activity of crizanlizumab at physiological conditions through a pH-dependent aspartic acid isomerization reaction
por: Bickel, Fabian, et al.
Publicado: (2022)

P1441: REAL-WORLD OUTCOMES AND DIGITALLY MONITORED QUALITY OF LIFE IN CRIZANLIZUMAB-TREATED PATIENTS WITH SICKLE CELL DISEASE.
por: Summers, Kim, et al.
Publicado: (2023)

The Kinetics of L-selectin Tethers and the Mechanics of Selectin-mediated Rolling
por: Alon, Ronen, et al.
Publicado: (1997)

More Unnecessary Imaginary Worlds – Part 4: The ICER Evidence Report for Crizanlizumab, Voxelotor and L-Glutamine for Sickle Cell Disease
por: Langley, Paul C
Publicado: (2020)

Targeted Gene Disruption Demonstrates That P-Selectin Glycoprotein Ligand 1 (Psgl-1) Is Required for P-Selectin–Mediated but Not E-Selectin–Mediated Neutrophil Rolling and Migration
por: Yang, Jing, et al.
Publicado: (1999)

Levels of Serum Soluble P-Selectin and E-Selectin in Psoriatıc Patients
por: Ataseven, Arzu, et al.
Publicado: (2014)

P-Selectin Glycoprotein Ligand-1 Forms Dimeric Interactions with E-Selectin but Monomeric Interactions with L-Selectin on Cell Surfaces
por: Zhang, Yan, et al.
Publicado: (2013)

Bromelain Decreases Neutrophil Interactions with P-Selectin, but Not E-Selectin, In Vitro by Proteolytic Cleavage of P-Selectin Glycoprotein Ligand-1
por: Banks, Jessica M., et al.
Publicado: (2013)

S268: INTERIM ANALYSIS OF A PHASE 2 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF CRIZANLIZUMAB IN SICKLE CELL DISEASE PATIENTS WITH PRIAPISM (SPARTAN)
por: Anderson, Alan, et al.
Publicado: (2023)

P1429: IN VITRO COMPARISON OF THE EFFECTS OF INCLACUMAB VS CRIZANLIZUMAB ON REDUCING ENDOTHELIAL ADHESION OF RED BLOOD CELLS IN STANDARDIZED MICROFLUIDIC PLATFORM
por: Federici, Chiara, et al.
Publicado: (2023)

Selectins with a catch
por: Wells, William A.
Publicado: (2003)

Selectin flexible cells
por: LeBrasseur, Nicole
Publicado: (2002)

Sensory assessment of Cercospora beticola sporulation for phenotyping the partial disease resistance of sugar beet genotypes
por: Oerke, Erich-Christian, et al.
Publicado: (2019)

The tumor microenvironment: the involvement of the selectin-selectin-ligand axis in tumor-endothelium interactions
por: Witz, Isaac P
Publicado: (2006)

Characterisation of Plasmodium falciparum populations selected on the human endothelial receptors P-selectin, E-selectin, CD9 and CD151
por: Metwally, Nahla Galal, et al.
Publicado: (2017)

The association of cell adhesion molecules and selectins (VCAM-1, ICAM-1, E-selectin, L-selectin, and P-selectin) with microvascular complications in patients with type 2 diabetes: A follow-up study
por: Siddiqui, Khalid, et al.
Publicado: (2023)

Endothelial dysfunction as a nexus for endothelial cell-cardiomyocyte miscommunication
por: Leucker, Thorsten M., et al.
Publicado: (2014)

Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review
por: Dick, Maurice H, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u9i4i2lemh5il6dhaggg2km4jc